BlueWillow Biologics
BlueWillow Biologics is a clinical-stage biotech developing intranasal vaccines using its proprietary NanoVax® nanoemulsion adjuvant platform, primarily serving U.S. government health agencies for pandemic preparedness and infectious disease applications.
- Company typePrivate
- Founded2012
- HeadquartersAnn Arbor, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BlueWillow Biologics does
BlueWillow Biologics, Inc. is a clinical-stage biopharmaceutical company headquartered in Ann Arbor, Michigan, developing intranasal vaccines based on its proprietary NanoVax® platform — an oil-in-water nanoemulsion adjuvant (designated W805EC, formerly NE01) that elicits a three-pronged mucosal, cellular, and systemic immune response with Th1 dominance. Originally founded as NanoBio Corporation in 2012 and rebranded in 2018, the company is advancing a broad pipeline of vaccine candidates including intranasal H5N1 (bird flu), anthrax (BW-1010, in partnership with Porton Biopharma), RSV, HSV-2, pertussis, tuberculosis, COVID-19 booster (with Medigen), peanut allergy, chlamydia, and therapeutic cancer vaccines. The technology is protected by multiple granted U.S. patents covering composition of matter and use across infectious disease and oncology applications, with several patents exclusively licensed from the University of Michigan.
BlueWillow serves primarily U.S. government health agencies — NIH/NIAID for research funding and BARDA for advanced development and procurement — with the strategic goal of supplying the Strategic National Stockpile for pandemic preparedness and bioterrorism countermeasures. The company's revenue model rests on three pillars: government contracts and grants (the dominant funding source, including NIAID awards worth up to $24 million for anthrax and up to $10.5 million for pandemic influenza), collaborative development agreements with strategic partners, and licensing royalties — most notably a 2013 license to Merck & Co. for use of the NE adjuvant in RSV and seasonal influenza vaccines. With 11-50 employees and no commercial product sales, BlueWillow operates as a research-driven organization whose near-term value creation depends on clinical milestone achievement, additional government contracts, and potential new licensing transactions.
BlueWillow Biologics firmographics
Firmographics- Name
- BlueWillow Biologics
- Legal name
- BlueWillow Biologics, Inc.
- Website
- https://bluewillow.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BlueWillow Biologics is a clinical-stage biotech developing intranasal vaccines using its proprietary NanoVax® nanoemulsion adjuvant platform, primarily serving U.S. government health agencies for pandemic preparedness and infectious disease applications.
- Ownership category
- akta.pro rank
BlueWillow Biologics industry classification
Industry- Product category
- Clinical-stage vaccine biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
- akta.pro secondary industries
- Vaccine Adjuvants & Formulation Systems (HLAIAEAI), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)
Keywords
Where BlueWillow Biologics is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BlueWillow Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Government Contracts & Grants: Primary revenue stream from NIH/NIAID research contracts and BARDA funding for vaccine development programs including anthrax, pandemic influenza, and other infectious disease vaccines.
- Licensing Royalties: Revenue from licensing proprietary nanoemulsion adjuvant technology to pharmaceutical partners such as Merck for use with RSV and seasonal influenza vaccines.
- Collaborative Development Agreements: Partnership-based development with Porton Biopharma Limited and other collaborators, funded through government contracts with potential milestone payments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BlueWillow Biologics product offering
Product offeringCore offering
BlueWillow Biologics is a clinical-stage biopharmaceutical company developing and commercializing intranasal vaccine candidates built on its proprietary NanoVax® W805EC oil-in-water nanoemulsion adjuvant platform. The platform elicits a three-pronged mucosal, cellular and systemic (Th1-dominant) immune response and is being applied to vaccines for pandemic influenza (H5N1), anthrax, RSV, HSV-2, pertussis, tuberculosis, COVID-19, chlamydia, peanut allergy, and cancer. The company primarily monetizes through government contracts, licensing royalties, and collaborative development agreements.
Product overview
BlueWillow Biologics is a clinical-stage biotech company that has developed a proprietary NanoVax technology platform centered on W805EC (NE01) oil-in-water nanoemulsion adjuvant for intranasal vaccine delivery. The platform elicits balanced mucosal, systemic and Th1 dominant cellular immune responses. The company is advancing multiple vaccine candidates across its pipeline including NanoVax W805EC adjuvanted A/H5 (bird flu) vaccine, BW-1010 intranasal anthrax vaccine, RSV vaccine, HSV-2 vaccine, pertussis vaccine, tuberculosis vaccine, COVID-19 booster (with Medigen), peanut allergy vaccine, chlamydia vaccine, and therapeutic cancer vaccine. The company also developed NanoStat technology as the predecessor nanoemulsion platform. All products leverage the core nanoemulsion adjuvant technology for intranasal delivery.
Differentiator
Problem solved
Functional benefit
Products and services
- NanoVax® Platform (W805EC) Proprietary oil-in-water nanoemulsion adjuvant and antigen delivery platform (W805EC) designed for intranasal vaccine delivery. Elicits a three-pronged mucosal, cellular, and systemic (Th1-dominant) immune response and is compatible with a broad array of viral, bacterial, and food antigens.
- NanoVax W805EC Adjuvanted A/H5 (Bird Flu) Influenza Vaccine Intranasal, adjuvanted H5N1 (bird flu) influenza vaccine candidate combining BlueWillow's NanoVax W805EC adjuvant with H5N1 antigens. Demonstrated safety and broad cross-clade immune priming in a Phase I clinical trial.
- BW-1010 Intranasal Anthrax Vaccine Intranasal recombinant protein vaccine candidate combining BlueWillow's NE01 nanoemulsion adjuvant with recombinant protective antigen (rPA) from Porton Biopharma Limited for protection against anthrax.
- Intranasal RSV Vaccine Intranasal nanoemulsion-adjuvanted respiratory syncytial virus vaccine candidate using whole inactivated RSV L19 strain combined with NE adjuvant, targeting a leading cause of childhood hospitalization globally.
- Intranasal HSV-2 Vaccine Intranasal nanoemulsion-adjuvanted herpes simplex virus-2 vaccine candidate for both prophylactic and therapeutic use; guinea pig studies showed 92% prevention of infection and viral latency.
- Intranasal Pertussis Vaccine
- Intranasal Tuberculosis Vaccine
- Intranasal COVID-19 Booster Vaccine Intranasal COVID-19 vaccine candidate developed in partnership with Medigen Vaccine Biologics that provides mucosal protection and boosts systemic immunity elicited from intramuscular COVID-19 vaccination.
- Intranasal Peanut Allergy Vaccine Therapeutic intranasal vaccine candidate combining purified peanut protein with the NanoVax system designed to reprogram the immune system to induce long-term suppression of allergic reactions, funded by an NIH Fast-Track SBIR contract.
- Intranasal Chlamydia Vaccine Intranasal NanoVax vaccine candidate for prevention of chlamydia, developed with antigen BD584 from McMaster University, targeting the 131 million annual new infections worldwide.
- Therapeutic Cancer Vaccine
Quantifiable outcome
- Phase I clinical trial demonstrated safety and broad immune responses in 40 healthy adults with effective cross-clade immune priming against multiple H5N1 strains.
- +3 more outcomes
Companies that use BlueWillow Biologics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
BlueWillow Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BlueWillow Biologics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- University of Maryland School of MedicinecoreClinical trial partner conducting the Phase I randomized trial for BlueWillow's intranasal H5N1 influenza vaccine candidate. Researchers published results in Nature Communications.
- Medigen Vaccine Biologics CorporationcorePartnership to develop intranasal vaccine for SARS-CoV-2 combining BlueWillow's NanoVax platform with Medigen's vaccine technology. Preclinical studies showed positive serum and mucosal immune response.
- McMaster University (Dr. James Mahony)minorResearch collaboration for chlamydia vaccine development combining BlueWillow's NanoVax technology with Dr. Mahony's novel BD584 antigen developed at McMaster University in Hamilton, Ontario.
- Porton Biopharma LimitedcoreStrategic partnership for development of next-generation NanoVax anthrax vaccine combining BlueWillow's intranasal adjuvant with Porton's recombinant protective antigen (rPA). Funded by NIAID contract worth up to $24 million over eight years.
- Public Health EnglandminorPartner with NanoBio and Porton Biopharma in producing a more effective anthrax vaccine through intranasal delivery with fewer doses required.
- Merck & Co.coreLicensed NE adjuvant to Merck for use in RSV and seasonal influenza vaccines, representing significant validation and revenue opportunity for the technology platform.
Scale indicators6 records
Recent moves7 records
Expansion highlights4 records
BlueWillow Biologics competitors and assessment
Company assessmentBroad incumbents
- Sanofi Pasteur: One of the world's largest vaccine companies with broad infectious disease portfolio including flu, RSV, and pandemic preparedness programs. Broad incumbent with potential partnership or competitive overlap.
- AstraZeneca (FluMist): Global vaccine incumbent whose FluMist intranasal influenza vaccine is the only FDA-approved needle-free flu vaccine. Sets the incumbent reference point BlueWillow must displace or differentiate against in intranasal flu.
- Merck & Co. Existing BlueWillow licensee for RSV and flu vaccines and one of the world's largest vaccine manufacturers. Both a commercial validator and a benchmark for what successful platform monetization looks like.
Direct peers
- Altimmune: Clinical-stage intranasal vaccine developer (NasoVAX influenza, T-COVID) with similar mucosal immunity thesis and pandemic preparedness positioning; directly comparable in business model, target indications, and government procurement pathway.
- Vaxart: Oral/mucosal vaccine developer focused on tablet-delivered vaccines targeting COVID, flu, and norovirus. Directly comparable as a non-injectable mucosal immunity platform pursuing similar infectious disease indications.
- Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated RSV vaccine (MV-012-968), directly overlapping with BlueWillow's intranasal RSV program and addressing the same pediatric respiratory indication.
Emerging players
- Bharat Biotech: India-based vaccine manufacturer that launched iNCOVACC, the world's first intranasal COVID-19 vaccine. A direct competitor in intranasal respiratory vaccines with established commercial-scale manufacturing capability.
- CanSino Biologics: Chinese vaccine developer with Convidecia Air, an approved intranasal adenoviral-vector COVID-19 vaccine. Direct competitive overlap in mucosal COVID vaccination and emerging pandemic preparedness markets.
- Intravacc: Dutch vaccine CDMO and intranasal platform developer with multiple mucosal vaccine programs. Comparable as an adjuvant/delivery platform company with similar government and academic partnership model.
- CureVac: mRNA vaccine developer pursuing flu and COVID programs. Indirect competitor in next-generation vaccine space, though with a different (mRNA vs. nanoemulsion adjuvant) technology approach targeting similar indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key highlights7 records
Customer concentration
BlueWillow Biologics social profiles
Digital presenceBlueWillow Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BlueWillow Biologics leadership team
Management profileNumber of profiles
Profiles7 records
BlueWillow Biologics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BlueWillow Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BlueWillow Biologics
What does BlueWillow Biologics do?
BlueWillow Biologics is a clinical-stage biopharmaceutical company developing and commercializing intranasal vaccine candidates built on its proprietary NanoVax® W805EC oil-in-water nanoemulsion adjuvant platform. The platform elicits a three-pronged mucosal, cellular and systemic (Th1-dominant) immune response and is being applied to vaccines for pandemic influenza (H5N1), anthrax, RSV, HSV-2, pertussis, tuberculosis, COVID-19, chlamydia, peanut allergy, and cancer. The company primarily monetizes through government contracts, licensing royalties, and collaborative development agreements.
Is BlueWillow Biologics a public or private company?
BlueWillow Biologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was BlueWillow Biologics founded?
BlueWillow Biologics was founded in 2012. It employs 11 to 50 people.
Where is BlueWillow Biologics based?
BlueWillow Biologics is headquartered in Ann Arbor, United States, in the North America region.
How does BlueWillow Biologics make money?
Three revenue lines are on record. Government Contracts & Grants are the primary driver. The others are licensing Royalties and collaborative Development Agreements.
Who are BlueWillow Biologics's main competitors?
Broad incumbents on record are Sanofi Pasteur, AstraZeneca (FluMist) and Merck & Co.. Direct peers are Altimmune, Vaxart and Meissa Vaccines. Emerging players are Bharat Biotech, CanSino Biologics, Intravacc and CureVac.
Does BlueWillow Biologics have an API?
No public API is recorded for BlueWillow Biologics.
What industry is BlueWillow Biologics in?
BlueWillow Biologics's product category is Clinical-stage vaccine biotechnology. Its primary akta.pro industry code is HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release), with a secondary code of HLAIAEAI, Vaccine Adjuvants & Formulation Systems. Its NAICS code is 325414 and its SIC code is 2836.